Global BRAHMS Procalcitonin (PCT) Market Size By Type (Procalcitonin�Antigen, Procalcitonin Antibody), By Application (Medical Industry, Veterinarian), By Region, And Segment Forecasts, 2023 to 2032

lobal BRAHMS Procalcitonin (PCT) Market Report Description

The Global BRAHMS Procalcitonin (PCT) Market was valued at USD 570 million in 2023 and is projected to surpass USD 1.04 billion by 2031, expanding at a CAGR of 7.8% during the forecast period from 2023 to 2031. The market is primarily driven by the increasing prevalence of sepsis and lower respiratory tract infections, rising demand for early and accurate diagnosis of bacterial infections, and growing adoption of PCT assays in intensive care units and emergency departments.

BRAHMS PCT is considered a highly specific biomarker for bacterial infection and sepsis diagnosis, enabling better differentiation between bacterial and viral infections and guiding appropriate antibiotic therapy. The growing concerns around antimicrobial resistance (AMR) further amplify the clinical need for PCT-based diagnostics.

Drivers

Rising Incidence of Sepsis and Bacterial Infections

Globally, the burden of sepsis and bloodstream infections is increasing, prompting the need for precise and timely diagnostic tools. BRAHMS PCT tests offer high sensitivity and specificity, supporting faster clinical decisions.

Growing Demand for Antibiotic Stewardship

Healthcare systems are increasingly emphasizing responsible antibiotic use. BRAHMS PCT assays support clinicians in minimizing unnecessary antibiotic prescriptions, thereby contributing to antibiotic stewardship programs.

Clinical Guidelines Supporting PCT Use

Numerous clinical guidelines from health authorities and medical societies now recommend PCT testing to improve diagnostic accuracy and reduce antibiotic overuse, enhancing its adoption in hospitals worldwide.

Restraints

High Cost of PCT Assays

Despite its diagnostic value, the relatively high cost of BRAHMS PCT tests can deter widespread adoption, especially in low- and middle-income countries where budget constraints limit access to advanced diagnostics.

Limited Awareness in Developing Regions

Lack of awareness and infrastructure to support biomarker-based diagnostics in emerging economies restricts the potential market growth, highlighting a gap in global healthcare equality.

Opportunity

Expansion in Point-of-Care and Decentralized Testing

The trend toward point-of-care testing and integration of PCT assays into rapid testing platforms provides opportunities to extend the reach of BRAHMS PCT beyond hospital laboratories into outpatient and primary care settings.

Emerging Markets Driving Demand

Countries in Asia-Pacific, Latin America, and the Middle East are ramping up investments in diagnostics and healthcare infrastructure, creating new avenues for BRAHMS PCT market penetration.

Market by System Type Insights

Based on system type, Automated Immunoassay Analyzers accounted for the largest market share in 2023. These systems enable high-throughput testing and integration into routine hospital workflows, making them the preferred method for PCT testing. The Point-of-Care Devices segment is expected to witness the fastest growth, driven by the need for rapid diagnostics in emergency and critical care settings.

Market by End-use Insights

In terms of end-use, Hospitals & Clinics dominated the market in 2023, benefiting from the rising cases of hospital-acquired infections and the need for rapid diagnostics in emergency departments. The Diagnostic Laboratories segment is also growing steadily, supported by increased outsourcing of testing services and expansion of centralized labs.

Market by Regional Insights

North America led the BRAHMS PCT market in 2023, driven by strong healthcare infrastructure, high sepsis prevalence, and early adoption of diagnostic innovations. However, Asia-Pacific is projected to experience the fastest growth, fueled by expanding healthcare coverage, rising awareness of bacterial infections, and government-led diagnostic initiatives.

Competitive Scenario

Key players in the global BRAHMS Procalcitonin market include Thermo Fisher Scientific (BRAHMS GmbH), bioMérieux SA, Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers. These companies are actively investing in R&D, clinical validation studies, and geographic expansion.

Notable Developments:

In 2023, Thermo Fisher Scientific launched an enhanced version of the BRAHMS PCT sensitive assay compatible with advanced immunoassay platforms.

Roche introduced an integrated PCT testing module in its COBAS series for real-time infection diagnostics.

In 2024, bioMérieux expanded its PCT assay compatibility across a wider range of laboratory automation systems.

Scope of Work – Global BRAHMS Procalcitonin (PCT) Market

Key Market Developments

2023: Thermo Fisher launched a next-gen BRAHMS PCT ultra-sensitive test for early sepsis detection.

2024: bioMérieux signed a strategic partnership with a global diagnostics chain to expand PCT-based protocols across 200+ labs.

2025: Roche Diagnostics rolled out a bundled infection management suite combining PCT with CRP and IL-6 on one platform for emergency departments.

FAQs

What is the current market size of the Global BRAHMS Procalcitonin (PCT) Market?

The market was valued at USD 570 million in 2023.

What is the major growth driver of the Global BRAHMS Procalcitonin (PCT) Market?

Rising global incidence of sepsis and increased focus on antibiotic stewardship are key drivers.

Which is the largest region during the forecast period in the Global BRAHMS Procalcitonin (PCT) Market?

North America held the largest share in 2023, but Asia-Pacific is expected to grow the fastest.

Which segment accounted for the largest market share in Global BRAHMS Procalcitonin (PCT) Market?

Automated Immunoassay Analyzers accounted for the largest market share by system type in 2023.

Who are the key market players in the Global BRAHMS Procalcitonin (PCT) Market?

Thermo Fisher Scientific, bioMérieux SA, Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers.

Would you like this content exported into a document format (e.g., Word or PDF)?